1.Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study.
Yuanchao ZHU ; Fei ZHAO ; Yubing ZHU ; Xingang LI ; Deshi DONG ; Bolin ZHU ; Jianchun LI ; Xin HU ; Zinan ZHAO ; Wenfeng XU ; Yang JV ; Dandan WANG ; Yingming ZHENG ; Yiwen DONG ; Lu LI ; Shilei YANG ; Zhiyuan TENG ; Ling LU ; Jingwei ZHU ; Linzhe DU ; Yunxin LIU ; Lechuan JIA ; Qiujv ZHANG ; Hui MA ; Ana ZHAO ; Hongliu JIANG ; Xin XU ; Jinli WANG ; Xuping QIAN ; Wei ZHANG ; Tingting ZHENG ; Chunxia YANG ; Xuguang CHEN ; Kun LIU ; Huanhuan JIANG ; Dongxiang QU ; Jia SONG ; Hua CHENG ; Wenfang SUN ; Hanqiu ZHAN ; Xiao LI ; Yafeng WANG ; Aixia WANG ; Li LIU ; Lihua YANG ; Nan ZHANG ; Shumin CHEN ; Jingjing MA ; Wei LIU ; Xiaoxiang DU ; Meiqin ZHENG ; Liyan WAN ; Guangqing DU ; Hangmei LIU ; Pengfei JIN
Acta Pharmaceutica Sinica B 2025;15(1):123-132
Debates persist regarding the efficacy and safety of azvudine, particularly its real-world outcomes. This study involved patients aged ≥60 years who were admitted to 25 hospitals in mainland China with confirmed SARS-CoV-2 infection between December 1, 2022, and February 28, 2023. Efficacy outcomes were all-cause mortality during hospitalization, the proportion of patients discharged with recovery, time to nucleic acid-negative conversion (T NANC), time to symptom improvement (T SI), and time of hospital stay (T HS). Safety was also assessed. Among the 5884 participants identified, 1999 received azvudine, and 1999 matched controls were included after exclusion and propensity score matching. Azvudine recipients exhibited lower all-cause mortality compared with controls in the overall population (13.3% vs. 17.1%, RR, 0.78; 95% CI, 0.67-0.90; P = 0.001) and in the severe subgroup (25.7% vs. 33.7%; RR, 0.76; 95% CI, 0.66-0.88; P < 0.001). A higher proportion of patients discharged with recovery, and a shorter T NANC were associated with azvudine recipients, especially in the severe subgroup. The incidence of adverse events in azvudine recipients was comparable to that in the control group (2.3% vs. 1.7%, P = 0.170). In conclusion, azvudine showed efficacy and safety in older patients hospitalized with COVID-19 during the SARS-CoV-2 omicron wave in China.
2.Laboratory analysis on 4 cases of sporadic Vibrio vulnificus infection in Shantou City
Lechuan CHEN ; Hongjun ZHU ; Zeyan ZHOU ; Yongjian KE ; Chuanwen CHEN
Chinese Journal of Infection Control 2016;15(4):272-276
Objective To analyze characteristics of pathogenic microbiology and antimicrobial susceptibility of Vib-rio vulnificus (V.vulnificus)causing infection in patients at a hospital in Shantou City. Methods Four patients with V.vulnificus infection admitted to a hospital between June 2013 and June 2014 were analyzed retrospectively, blood specimens of patients were collected for culture,blister fluid and wound secretion were taken and inoculated on blood agar plates,MacConkey agar plates,and thiosulfate citrate bile salts sucrose (TCBS)plates,isolated strains were identified and performed antimicrobial susceptibility testing. Results Among 4 patients with V. vulnificus infection,3 died,1 was cured;patients developed primary septicemia and lower extremity infection be-cause of eating pickled crab,steamed scallop,or contacting with seafood products after trauma. Blister fluid from patients A and B,wound secretion from patient C,and blood from patient D were all isolated oxidase-positive gram-negative bacteria which produced green colonies on TCBS plate,these strains were identified as V.vulnificus, which were resistant or intermediate to cefazolin,intermediate to cefotetan,and 1 strain was resistant to cefepime. Conclusion Four patients infected with V.vulnificus have high mortality rate (3/4),positive rates of blister fluid and wound secretion are higher than blood;timely medical consultation,early antimicrobial therapy,and active de-bridement will help to cure the disease.
3.Optimal design of portable ambulatory blood pressure monitor based on STM32L.
Mengxing LIU ; Lechuan ZHOU ; Chao HUANG ; Shuming YE ; Hang CHEN
Chinese Journal of Medical Instrumentation 2014;38(5):345-349
Based on the 32-bit ultra low power microcontroller STM32L151RBT6 using ARM Cortex-M3 kernel, the portable ambulatory blood pressure monitor powered by two AA batteries was designed. In order to insure the stability of power supply and prevent overpressure of cuff, super capacitor technology and new kind of safety logic circuits were used. The experimental result shows that: this solution is accurate and stable, which has high safety coefficient and a great clinical application value.
Blood Pressure Monitoring, Ambulatory
;
instrumentation
;
Equipment Design
;
Humans
;
Software
4.Optimal Design of Portable Ambulatory Blood Pressure Monitor Based on STM32L
Mengxing LIU ; Lechuan ZHOU ; Chao HUANG ; Shuming YE ; Hang CHEN
Chinese Journal of Medical Instrumentation 2014;(5):345-349
Based on the 32-bit ultra low power microcontroler STM32L151RBT6 using ARM Cortex-M3 kernel, the portable ambulatory blood pressure monitor powered by two AA batteries was designed. In order to insure the stability of power supply and prevent overpressure of cuff, super capacitor technology and new kind of safety logic circuits were used. The experimental result shows that: this solution is accurate and stable, which has high safety coefficient and a great clinical application value.

Result Analysis
Print
Save
E-mail